Physician profile
Douglas Wu
NPI 1861874885
$163,405.00
in general payments reported to CMS, 2019-2025
7 companies · $19K in 2025
The $19K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,564 · 2020: $16K · 2021: $99K · 2022: $8,328 · 2023: $9,499 · 2024: $8,080 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $27K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,200 · Travel and Lodging: $3,808 · Food and Beverage: $767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $27,331.32 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,200.00 |
| Travel and Lodging | $3,807.92 |
| Food and Beverage | $767.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $115,352.37 | 2019-2023 | |
| Abbvie INC. | $18,243.37 | 2023-2025 | Botox |
| Solta Medical, A Division of Bausch Health US, LLC | $17,753.70 | 2025 | |
| Allergan, INC. | $11,955.96 | 2019-2022 | |
| Revance Therapeutics, INC. | $54.80 | 2024-2025 | Daxxify |
| Biofrontera INC. | $23.74 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
| Merz North America, INC. | $21.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.